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Abstract
Background: Type 1 diabetes is a multifactorial disease with a strong genetic component. The aim of the study
was to assess the impact of single nucleotide polymorphisms (SNPs) in several genes as susceptible markers in the
risk of type 1 diabetes in the Estonian population. Methods: The rs6679677 (1p13), rs17696736 (12q24) and
rs763361 (18q22) were genotyped in a total of 230 controls and 154 type 1 diabetes patients of Estonian origin.
Results: The rs6679677 A (OR = 2.13, 95%CI = 1.48-3.08, p = 0.00001), rs17696736 G (OR = 1.53, 95%CI = 1.14-2.04,
p = 0.0046) and rs763361 T (OR = 1.48, 95%CI = 1.11-1.98, p = 0.0084) alleles were associated with risk of type 1
diabetes.
Conclusions: The current study supports the rs6679677 (PHTF1-PTPN22), rs17696736 (C12orf30) and rs763361
(CD226) SNPs as susceptibility factors for type 1 diabetes outside the major histocompatibility region (MHC) region.
The full study had 80% or above to detect an odds ratio of 1.8 under the assumption of an additive model at type
1 error rate, a = 0.05.
Background
The genetic predisposition to type 1 diabetes is strongly
linked to MHC region [1] but non - MHC locus asso-
ciated genes are also considered to predispose in the
risk of type 1 diabetes. Evidence strongly supports the
insulin gene [2], the CTLA-4 locus [3] and the PTPN22
gene [4] as important candidates outside the MHC
r e g i o n .M e a n w h i l e ,t h ee s t a b l ished genetic associations
with type 1 diabetes explain roughly half of the genetic
risk for type 1 diabetes, indicating that other loci exist.
In favor of it, genome wide association studies have
recently reported new chromosomal regions and novel
candidates in the risk of type 1 diabetes [5,6]. Of note,
within the CD226 gene (18q22) the rs763361 SNP was
found to be associated with type 1 diabetes [5]. The
CD226 gene is expressed on the majority of immune
cells including natural killer (NK) cells and T cells
mediating their activation and differentiation [7]. More-
over, the rs17696736 and the rs6679677 in the chromo-
somal regions of 12q24 and 1q13 respectively, were also
reported to be associated with type 1 diabetes [8]. In
particular, the rs17696736 SNP (C12orf30 gene) is
located within a large linkage disequilibrium (LD) block
that contains several genes of possible function rele-
vance to type 1 diabetes [8]. The rs6679677 SNP is an
intergenic SNP located downstream of the round sper-
matid basic protein 1 (RSBN1) and in the promoter site
of the putative homeodomain transcription factor 1
(PHTF1) gene. The complexity of type 1 diabetes, the
heterogeneity of allele frequencies across populations
and the difficulties to localize the true causative variants
within a LD block recommends the replication analysis
of reported SNPs in order to establish their impact on
individual ethnic groups. In the current study we sought
to replicate recently reported associations from the gen-
ome wide association (GWA) studies in order to evalu-
ate their impact as possible candidates in the risk of
type 1 diabetes in Estonian population.
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Subjects
An ethnically homogenous population of Estonian origin
including 230 controls (mean age 45.9 ± 14.5 years, 139
females) and 154 type 1 diabetes patients (mean age at
diagnosis 22.0 ± 14.3 years, 77 females) were enrolled
into a case-control study. Estonia is situated in the
north of Europe, on the eastern shores of the Baltic Sea
and Estonians belong to the Finno-Ugric ethnic group.
Of note, our population cohort is originated from Saare-
maa County in Estonia. Saaremaa is the biggest island of
Estonia where the population has been relatively perma-
nent over generations compared to the major mainland
regions in Estonia. All patients with type 1 diabetes
were diagnosed according to the criteria established by
the Expert Committee on the Diagnosis and Classifica-
tion of Diabetes Mellitus [9]. The Ethics Committee of
the University of Tartu approved the study, and
informed consent was obtained from all participants.
Genotyping
The genotyping of rs6679677 (PHTF1-PTPN22),
rs17696736 (C12orf30) and rs763361 (CD226) SNPs was
carried out using the SNP genotyping assay (Applied
Biosystems, Foster City, CA). PCR reactions were run
on the ABI 7000 instrument (Applied Biosystems) using
the following cycling parameters: after the first step at
95°C for 10 min, 40 cycles of denaturation at 92°C for
15 s and extension at 60°C for 1 min and the genotypes
were analysed using the allelic discrimination function
of the instrument. A 100% genotyping success rate was
obtained for all studied SNPs.
Statistical analysis
The R (version 2.4.1) statistical computer program (The
R Foundation for Statistical Computing, Boston, MA,
http://www.r-project.org) was employed to obtain odds
ratio (OR) values as well as Wald’sc o n f i d e n c ei n t e r v a l s
(CI) for alleles and genotypes. Hardy-Weinberg equili-
brium (HWE) was performed using the SHEsis software
[10]. Permutation analysis was performed using the
Haploview 3.2 version software [11]. 10000 permutations
were carried out to estimate the significance of the
results, correcting for the three loci tested. Power calcu-
lations were performed using the PS software [12]. A p
value of < 0.05 was considered significant for all
analyses.
Results
The rs6679677, rs17696736 and rs763361 SNPs were
genotyped in all studied subjects and the analysis of
genotypes distribution showed no significant deviation
from the HWE in type 1 diabetes or in the control
group (p > 0.05). A significant higher frequency of the
rs6679677 AA (OR = 4.23, 95%CI = 1.56-11.52, p =
0.0047), rs17696736 GG (OR = 2.32, 95%CI = 1.25-4.28,
p = 0.0074) and rs763361 TT (OR = 2.29, 95%CI =
1.25-4.18, p = 0.0071) genotype was observed in the
group of type 1 diabetes patients when compared to
controls (table 1). Moreover, the distribution frequency
of the rs6679677 A (OR = 2.13, 95%CI = 1.48-3.08, p =
0.00001), rs17696736 G (OR = 1.53, 95%CI = 1.14-2.04,
p = 0.0046) and rs763361 T (OR = 1.48, 95%CI = 1.11-
1.98, p = 0.0084) allele was significantly higher in type 1
diabetes when compared with the control group (table
1). Power calculation analysis showed that given the fre-
quencies and genotype odds ratio observed in our popu-
lation for the homozygotes (high risk alleles), our case
control study had 85%, 89% and 90% power (at a =
0.05), to detect significant differences for the rs6679677,
rs1769676 and rs763361 markers, respectively. Of note,
all observed type 1 diabetes associations with the
rs6679677 A, rs17696736 G and rs763361 T alleles
remained significant after permutation analysis (10000
permutations, giving p = 0.0004, p = 0.016 and p =
0.034, respectively).
Table 1 Genotype and allele frequencies of the
rs6679677, rs17696736 and rs763361 SNPs in the type 1
diabetes patients and control subjects.
SNP
(Gene region)
Cases
(%)
(N = 154)
Control
(%)
(N = 230)
Odds ratio (95%
CI)
P
rs6679677
(PHTF1-
PTPN22)
AA 13(8.4) 6(2.6) 4.23(1.56-11.52) 0.0047
AC 53(34.5) 52(22.6) 1.99(1.26-3.16) 0.0034
CC 88(57.1) 172(74.8) 1*
A 79(25.6) 64(13.9) 2.13(1.48-3.08) 0.00001
C 229(74.4) 396(86.1) 1*
rs17696736
(C12orf30)
AA 38(24.7) 88(38.3) 1*
AG 83(53.9) 109(47.4) 1.76(1.10-2.84) 0.0194
GG 33(21.4) 33(14.3) 2.32(1.25-4.28) 0.0074
A 159(51.6) 285(61.9) 1*
G 149(48.4) 175(38.1) 1.53(1.14-2.04) 0.0046
rs763361
(CD226)
CC 36(23.4) 76(33.1) 1*
CT 79(51.3) 118(51.3) 1.41(0.87-2.30) 0.16
TT 39(25.3) 36(15.6) 2.29(1.25-4.18) 0.0071
C 151(49.1) 270(58.7) 1*
T 157(50.9) 190(41.3) 1.48(1.11-1.98) 0.0084
1*: referent estimate
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In the present study we attempted to assess the impact
of novel reported findings from genome wide type 1 dia-
betes association studies in a population of Estonian ori-
gin. In favor of it, the association of the rs6679677 SNP
in susceptibility of type 1 diabetes has been confirmed;
thus making it an additional candidate within the 1q13
region. Notably, the rs6679677 SNP is located in the
same haplotype block with the rs2476601 SNP of the
PTPN22 gene. Having previously demonstrated a signifi-
cant association of T allele of rs2476601 SNP in type 1
diabetes [13], we sought to assess the hypothesis that
the rs2476601 SNP might not be the sole causal variant
in the region. However, according to our previous find-
ings [13] and based on the genetic data alone, we were
unable to distinguish between the two studied SNPs
since they are in perfect LD (R
2 = 1.00, D’ = 1.00). This
is in correlation with the results of recent studies in
which an association of the rs6679677 SNP with type 1
diabetes has also been reported and the effects of the
two SNPs could not be distinguished due to tight LD
[14,15]. Moreover, through using the Genomatix web
tool for SNP analysis http://www.genomatix.de, as Qu et
al. demonstrated [15], we revealed that the substitution
of cytosine (C) to adenine (A) in the rs6679677 locus
predicts the loss of two (CAAT, CDP) and the genera-
tion of one (Sox-5) transcription binding sites. In addi-
tion we agree with Qu et al. [15] that the region around
PTPN22 may harbor additional disease related alleles
not yet found.
Furthermore, we confirmed that the rs763361 SNP in
the CD226 gene was associated with susceptibility to
type 1 diabetes. The rs763361 SNP is predicted to be a
functional SNP, residing in the final 3’ of the exon 7
and alters the exon splicing silencer (ESS) sequence [5].
The disease-susceptible minor allele A, which encodes
Ser307, maintains the wild type ESS sequence and com-
pared to the resistant Gly307 allele would have a higher
silencer function that reduces the productive splicing of
exons 6 and 7. Notably, the CD226 molecule is
expressed on a variety of hematopoietic cells and inter-
action with its ligands poliovirus receptor (PVR, CD155)
and Nectin-2 (CD112) results in a variety of cellular
responses of innate and adaptive immunity [16].
Recently, new studies have provided additional evidence
and support the role of rs763361 SNP in the risk of
autoimmune thyroid disease [17], rheumatoid arthritis,
multiple sclerosis [18,19] and Wegener’s granulomatosis
[19].
Moreover, we showed that the rs17696736 SNP in the
C12orf30 gene also contribute to susceptibility of type 1
diabetes. Interestingly, the C120rf30 gene maps into a
region of extensive linkage disequilibrium including
several genes that represent functional candidates of
type 1 diabetes-susceptibility because of their presumed
roles in immune signaling. Remarkably, the SH2B3
(SH2B adaptor protein 3), TRAFD1 (TRAF-type zinc
finger domain containing 1) and PTPN11 (protein tyro-
sine phosphatase, non-receptor type 11) map on the
same region with the C12orf30 gene. Therefore, for this
region in particular, extensive resequencing, further gen-
otyping and targeted functional studies will be essential
steps in identifying which gene, or genes, are causal.
O n ec o m m o ni s s u ei nt h es t u d yo fc o m p l e xd i s e a s e s ,
including type 1 diabetes, is the limited sample size,
resulting in adequate power to detect association or the
risk of false positive results. Typically, the full study had
80% power or above to detect an odds ratio of 1.8
under the assumption of an additive model at type 1
error rate, a = 0.05. Further, take in consideration the
sample size of our study, permutation analysis has been
applied in order to evaluate the impact of our findings.
Of note, all the reported associations remained signifi-
cant after applied permutation analysis.
Noticeably, further genotyping, resequencing and fine
mapping could assist in clarifying the true causative
genes within a strong LD block and could reveal new
susceptible allelic variants for type 1 diabetes. The
potential of the latter approaches to detect new associa-
tions have recently been demonstrated by Nejentsev et
al [20]. Moreover, we should also take into account that
due to allelic heterogeneity, there is a variation in risk
allele frequencies between populations, which may
account for differences in disease prevalence between
ethnic groups.
Conclusion
In the current study, we have demonstrated a significant
association between recently reported SNPs and type 1
diabetes in Estonian population. To confirm our find-
ings, further associated studies are needed to elucidate
the functional role of these SNPs as likely mediators for
autoimmunity and as potential therapeutic targets for
antidiabetic drugs. The probability that the newly
reported loci with type 1 diabetes may predispose other
autoimmune diseases should also be examined.
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